Miquéias Lopes-Pacheco

Contactos

Instituto de Biosistemas e Ciências Integrativas

Sala/Gabinete 8.2.50
Ext. Principal 28250
Email mlpacheco@ciencias.ulisboa.pt

Carreira Investigacao
Categoria Investigador Doutorado Contratado ao Abrigo do DL57

Indicadores

ResearcherID
Orcid
Scopus
Google Scholar

Palavras Chave

Keywords


Currículo Resumido

Dr. Lopes-Pacheco is a Biomedicinal Scientist (2009) with a Specialization in Clinical Pharmacology (2011). He took his Master’s degree (2012) and Ph.D. (2016) in Biological Sciences (Biophysics) at the Federal University of Rio de Janeiro, Brazil with an International Ph.D. Internship (2013-2014) at the Johns Hopkins University, USA. Currently, he is a Junior Investigator at the University of Lisbon, Portugal. He has technical expertise in cell culture, animal models, high throughput screening, molecular biology and biochemical assays, histology (light and fluorescence microscopy), and lung mechanics. By now, he has published 35 peer-reviewed papers (H-index: 15 in Scopus, 17 in Google Scholars), being the first author (co-author) in 16. He has presented his work at several high-level scientific meetings, being an invited speaker in two 'Multidisciplinar Brazilian Conferences of Cystic Fibrosis'. He has received several international awards, including the 2018 Gilead Sciences Research Scholar for Cystic Fibrosis - the first non-USA-based researcher to receive this Award. He is also a Guest Associate Editor in Frontiers in Pharmacology Journal (Research Topics “Emerging Therapeutic Approaches for Cystic Fibrosis” [completed] and "Advances in Cell-Based and Gene-Based Therapies for Respiratory Diseases" [ongoing]). Finally, Dr. Lopes-Pacheco has participated in cystic fibrosis awareness activities to disseminate the knowledge obtained by his work and strengthening the communication between scientific and lay audiences.


Scientific Interests

Dr. Lopes-Pacheco's research is focused on: 1) understanding the molecular and cellular mechanisms that lead to degradation and/or dysfunction of CFTR mutants, 2) developing novel pharmacological therapies for cystic fibrosis, and 3) investigating cell-based and gene-based therapies for respiratory diseases (acute respiratory distress syndrome, allergic asthma, chronic obstructive pulmonary disease, cystic fibrosis, silicosis).


Publicações selecionadas
  • Lopes-Pacheco M. "CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine". Front Pharmacol , 2020; 10: 1662. doi: 10.3389/fphar.2019.01662.
  • Lopes-Pacheco M, Silva IAL, Turner MJ, Carlile GW, Sondo E, Thomas DY, Pedemonte N, Hanrahan JW, Amaral MD. "Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR". Biochem Pharmacol, 2020; 180: 114133. doi: 10.1016/j.bcp.2020.114133.
  • Lopes-Pacheco M, Robba C, Rocco PRM, Pelosi P. "Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome". Cell Biol Toxicol, 2020; 36: 83-102. doi: 10.1007/s10565-019-09493-5.
  • Lopes-Pacheco M, Boinot C, Sabirzhanova I, Rapino D, Cebotaru L. "Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis". Cell Physiol Biochem, 2017; 41: 2194-2210. doi: 10.1159/000475578.
  • Lopes-Pacheco M, Xisto DG, Ornellas FM, Antunes MA, Abreu SC, Rocco PR, Takiya CM, Morales MM. "Repeated administration of bone marrow-derived cells prevents disease progression in experimental silicosis". Cell Physiol Biochem, 2013; 32: 1681-1694. doi: 10.1159/000356603.

Ver todas as Publicações